- Home
- IPSC vs INMB Comparison
IPSC vs INMB Comparison
Compare IPSC & INMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPSC
- INMB
- Stock Information
- Founded
- IPSC 2019
- INMB 2015
- Country
- IPSC United States
- INMB United States
- Employees
- IPSC N/A
- INMB 17
- Industry
- IPSC Medicinal Chemicals and Botanical Products
- INMB Biotechnology: Pharmaceutical Preparations
- Sector
- IPSC Health Care
- INMB Health Care
- Exchange
- IPSC Nasdaq
- INMB Nasdaq
- Market Cap
- IPSC 149.1M
- INMB 103.3M
- IPO Year
- IPSC 2021
- INMB 2019
- Fundamental
- Price
- IPSC $1.57
- INMB $5.00
- Analyst Decision
- IPSC Strong Buy
- INMB Buy
- Analyst Count
- IPSC 3
- INMB 1
- Target Price
- IPSC $15.00
- INMB $22.00
- AVG Volume (30 Days)
- IPSC 349.9K
- INMB 248.9K
- Earning Date
- IPSC 11-07-2024
- INMB 10-30-2024
- Dividend Yield
- IPSC N/A
- INMB N/A
- EPS Growth
- IPSC N/A
- INMB N/A
- EPS
- IPSC N/A
- INMB N/A
- Revenue
- IPSC $2,041,000.00
- INMB $85,000.00
- Revenue This Year
- IPSC $233.38
- INMB N/A
- Revenue Next Year
- IPSC $34.05
- INMB N/A
- P/E Ratio
- IPSC N/A
- INMB N/A
- Revenue Growth
- IPSC N/A
- INMB N/A
- 52 Week Low
- IPSC $1.28
- INMB $4.78
- 52 Week High
- IPSC $5.51
- INMB $14.74
- Technical
- Relative Strength Index (RSI)
- IPSC 49.88
- INMB 41.36
- Support Level
- IPSC $1.36
- INMB $4.78
- Resistance Level
- IPSC $1.56
- INMB $5.22
- Average True Range (ATR)
- IPSC 0.12
- INMB 0.27
- MACD
- IPSC 0.01
- INMB 0.04
- Stochastic Oscillator
- IPSC 42.00
- INMB 23.16
About IPSC Century Therapeutics Inc.
Century Therapeutics Inc is a biotechnology company specializes in leveraging adult stem cells to develop advanced cell therapy products targeting cancer, autoimmune, and inflammatory diseases. Their innovative approach involves a genetically engineered allogeneic cell therapy platform comprising induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and cutting-edge manufacturing capabilities. This comprehensive platform aims to overcome the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and minimizing development and supply risks.
About INMB INmune Bio Inc. Common stock
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products includeINKmune, INBO3, XPro1595, LIVNate, and others.